Gulsoy Kirnap, NazliTurhan Iyidir, OzlemBozkus, YusufIsildak, Serife MehlikaAnil, CuneydFirat, Sevde NurDemir, CananNar, AsliBascil, Tutuncu Neslihan2021-03-192021-03-1920201300-0144https://journals.tubitak.gov.tr/medical/issues/sag-20-50-4/sag-50-4-30-1902-176.pdfhttp://hdl.handle.net/11727/5573Background/aim: Overt thyroidism is known to cause neuropsychiatric disorders but studies on subclinical hyperthyroidism (SCH) are limited. Subclinical hyperthyroidism induction by administering L-Thyroxine (LT4) is the standard treatment method in differentiated thyroid carcinoma (DTC) follow-up. Our aim was to investigate whether anxiety, depression and quality of life are affected in DTC patients followed-up with exogenous SCH. Materials and methods: The patients were divided into exogenous SCH by LT4-DTC (n = 127), euthyroid-DTC (n = 66) and exogenous euthyroid-benign thyroid nodutile (BTN) who underwent thyroidectomy for benign thyroid pathology (n = 85) groups. Results: The rate of moderate/severe anxiety was significantly higher in SCH-DTC than euthyroid-BTN group (27.5%, n = 35 vs. 9.4%, n = 8) (P = 0.001). TSH levels and Beck anxiety inventory (BAI) scores were significantly negatively correlated(P = 0.009 r = -0.16). Free T4 and BAI were significantly positively correlated (P = 0.04 r = 0.4). The groups were similar in terms of depression severity (P = 0.15). Subclinical hyperthyroid-DTC group scored significantly lowerthan euthyroid-BTN group in all scales of SF-36 quality of life survey. Conclusion: LT4-induced SCH, which is a part of traditional DTC treatment, can exacerbate the anxiety symptoms in patients and disrupt their quality of life, depending on the level of fT4.enginfo:eu-repo/semantics/openAccessBeck anxiety and depression inventorydifferentiated thyroid carcinomaSF-36 quality of life surveysubclinical hyperthyroidismTSH suppressionarticle5048708760006130051000302-s2.0-85087019557